Corante

About this author
Zack Lynch is author of The Neuro Revolution: How Brain Science Is Changing Our World (St. Martin's Press, July 2009).
He is the founder and executive director of the Neurotechnology Industry Organization (NIO) and co-founder of NeuroInsights. He serves on the advisory boards of the McGovern Institute for Brain Research at MIT, the Center for Neuroeconomic Studies, Science Progress, and SocialText, a social software company. Please send newsworthy items or feedback - to Zack Lynch.
Follow me on Twitter at @neurorev
Receive by email

GUEST AUTHOR ARCHIVES
THE NEURO REVOLUTION
TNRCoverWeb120.jpg Buy on Amazon
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Brain Waves

« The Wiki Way - Collaborate with Socialtext Now | Main | How We Are Going to Die »

October 5, 2005

Neurotech in Japan and Emerging Schizophrenia Treatments

Email This Entry

Posted by Zack Lynch

Due to increasing interest in the neurotechnology industry from the Japanese market, NeuroInsights has entered an agreement with Japan's BioToday to translate and distribute the investment newsletter Neurotech Insights in Japanese. The latest issue focused on the Schizophrenia market was launched yesterday in both English and Japanese.
682.jpg

INSIDE THIS ISSUE: SEPTEMBER 30, 2005

Featured Topic: Schizophrenia Treatments: Is Newer Better
Included: Clinical Trials for Schizophrenia and Psychosis
Top News Alerts: Deals, Clinical Trials, & Stocks
Featured Company: Acadia Pharmaceuticals (ACAD)

Market summary: Stocks gain on alzheimer’s, schizophrenia, and insomnia news

The biggest winner in September was Memory Pharmaceuticals (MEMY), which announced that the safety portion of its Phase II trial for Alzheimer’s is complete and the efficacy portion of the trial will now begin (see MEMY, page 4). ACADIA (ACAD) was also up this month on steady progress of their schizophrenia pipeline. NeuroInsights spoke with CEO, Uli Hacksell, and thinks ACADIA is in a good position to continue its upward climb (see ACADIA, page 6)…more

Schizophrenia: NIMH STUDY COMPARES Treatments, better options Coming

The much anticipated results of a large study of schizophrenia drugs dubbed CATIE for “Clinical Antipsychotic Trials in Intervention Effectiveness” were announced in the September 22 issue of the New England Journal of Medicine. Newer atypical antipsychotics including Eli-Lilly’s (LLY) Zyprexa, Johnson & Johnson’s (JNJ) Risperdal, AstraZeneca’s (AZN) Seroquel and Pfizer’s (PFE) Geodon were compared to the older antipsychotic perphenazine, which was introduced in the 1950's. Patients who failed with all drugs were switched to Abilify, the latest drug from Bristol-Myers Squibb (BMY)…

Foundations Accelerate Research and Treatments for Mental Illness

The role of organized philanthropy in mental health in the United States can be traced to the early 1900s when the Rockefeller Foundation and the Milbank Memorial Fund helped establish the National Committee for Mental Hygiene in 1909. Several decades later in 1942, the Albert and Mary Lasker Foundation used extensive connections in Congress to inspire the legislation that authorized establishment of the National Institute of Mental Health (NIMH)…

ACADIA Pharma: A new approach to mental illness

ACADIA Pharmaceuticals, Inc. (ACAD) is a small company with an international presence. It is focused on schizophrenia, a huge market with a large unmet medical need. Located in San Diego, CA, with chemistry facilities in Malmo, Sweden, the company has several drugs in the clinic that promise to revolutionize the approach to mental illness…

Neurobiological technologies Presents at MCF Investor summit: sells XERECEPT RIGHTS TO CELTIC

Neurobiological Technologies, Inc (NTII) CEO, Paul Freiman, presented an intriguing story this week at the Merriman, Curhan, Ford Investor Summit in San Francisco. Citing the legendary fact that only 10 in 1000 drugs make it to clinical trials and only one out of those will actually be approved, NTI’s strategy is to in-license late stage drugs and take them through regulatory approval alone or in partnership with global marketers. So far NTI’s strategy is paying off. With only 25 employees and no basic research effort, they have one partnered drug on the market, two late stage trials underway and a full bank account, thanks to a recent $33 million deal and a $10 million credit line with Comerica…

Integra LifeSciences Acquires RADIONICS & EUNOE

Integra LifeSciences Holdings Corporation (IART) has been busy acquiring more assets this month, beefing up its product line and revenue projections. The 1,300 person, New Jersey company develops, manufactures, and markets medical devices for the neuro-trauma, neurosurgery, reconstructive surgery and general surgery markets…

To purchase this issue of Neurotech Insights or back issues on Stem Cells, Stroke and Pain click here.



Comments (1) + TrackBacks (0) | Category: Neurotech Industry


COMMENTS

1. guy potter on September 28, 2006 4:41 PM writes...


I have tried abilify and all it did is make
me blurt out things incoherently. when will
better treatment be available?? starkeep@hotmail.com

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Chinese Cover of The Neuro Revolution
The Neuro Revolution Lands In China
How Neuroscience Will Change the World - My Interview on Reason.tv
Neuroscience Hearing on Capitol Hill Wednesday Sept 29, 2pm
The Neuro Revolution Published in Japan as "Neuro Wars"
Neurotech 2010: Translational Researchers Highlight Innovation
The Neuro Revolution in China Progressing
Speakers for Neurotech 2010 - Boston, May 19-20